Category - Developments

Developments

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Mateon Therapeutics’ (NASDAQ:MATN) OT-101 received FDA pediatric disease designation for the treatment of diffuse intrinsic pontine glioma (DIPG). DIPG is a rare pediatric brainstem tumor that has a very low survival...

September 24, 2019

Developments

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Ovid Therapeutics (NASDAQ:OVID) reported positive initial data from its Phase 2 study of soticlestat, a cholesterol 24-hydroxylase inhibitor, in patients with rare developmental and epileptic encephalopathies (DEE). ...

September 24, 2019

Developments

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

Aldeyra Therapeutics’ (NASDAQ:ALDX) ADX-2191 received FDA fast track designation for the prevention of proliferative vitreoretinopathy (PVR). PVR is an inflammatory disorder of the retina that leads to severe retinal...

September 24, 2019

Developments

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

Ocular Therapeutix (NASDAQ:OCUL) has dosed the first patients in its Phase 3 efficacy trial of DEXTENZA for the treatment of symptoms of allergic conjunctivitis (AC). DEXTENZA is a corticosteroid that is FDA-approved...

September 24, 2019

Developments

MDACC begins dosing pancreatic cancer patients in Phase 1b trial of Soricimed’s SOR-C13

Closely-held Soricimed reported that The University of Texas MD Anderson Cancer Center (MDACC) has begun dosing the first cohort of three late-stage pancreatic cancer patients in its investigator-initiated trial of SOR...

September 24, 2019

Developments

Zenabis receives final license amendment for Zenabis Atholville site

Zenabis Global (TSX:ZENA) has received the licensing of Phase 2C – Part 2 at its Zenabis Atholville site in New Brunswick for an additional 3,000 kg of licensed annual cultivation capacity of cannabis. The amendment...

September 23, 2019

Developments

BeyondSpring to present superior product data in breast cancer neutropenia prevention

BeyondSpring’s (NASDAQ:BYSI) poster with findings from its Study 106 has been accepted for presentation at this year’s European Society for Medical Oncology Congress in Barcelona on Sept. 28. In Study 106, BeyondSpring...

September 23, 2019

Developments

Aerie Pharma receives positive CHMP opinion for Rhokiinsa in EU

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended approval of Aerie Pharmaceuticals’ (NASDAQ:AERI) marketing authorization application (MAA) for Rhokiinsa solution. The...

September 20, 2019

Developments

BriaCell presents remarkable responder data in combo study with KEYTRUDA

Dr. William Williams, president and CEO of BriaCell Therapeutics (TSX-V:BCT; OTCQB:BCTXF) presented clinical updates of its Phase 1/2a clinical trial of Bria-IMT, its lead drug candidate, in a combination study with...

September 19, 2019

Developments

Zynerba Pharma reports positive topline Phase 2 Zygel efficacy data

Zynerba Pharmaceuticals (NASDAQ:ZYNE) reported positive topline efficacy results, along with safety profile issues, from its open label Phase 2 study assessing the safety and efficacy of Zygel in developmental and...

September 19, 2019

Category - Developments

Mateon Therapeutics gets FDA pediatric disease designation for DIPG drug candidate

Ovid Therapeutics reports positive initial data from Phase 2 epilepsy trial

Aldeyra gets FDA fast track designation for vitreoretinopathy drug candidate

Ocular Therapeutix doses first patient in Phase 3 allergic conjunctivitis trial

MDACC begins dosing pancreatic cancer patients in Phase 1b trial of Soricimed’s SOR-C13

Zenabis receives final license amendment for Zenabis Atholville site

BeyondSpring to present superior product data in breast cancer neutropenia prevention

Aerie Pharma receives positive CHMP opinion for Rhokiinsa in EU

BriaCell presents remarkable responder data in combo study with KEYTRUDA

Zynerba Pharma reports positive topline Phase 2 Zygel efficacy data

General

More